Literature DB >> 26574489

Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.

I D Zoet1, N K H de Boer2, T G J de Meij3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26574489      PMCID： PMC4957470          DOI： 10.1093/ecco-jcc/jjv205

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  5 in total

1.  Developmental effects on the adolescent of a temporary ileostomy.

Authors:  R C Manworren
Journal:  J Wound Ostomy Continence Nurs       Date:  1996-07       Impact factor: 1.741

2.  Quality of life in patients postcolectomy for pediatric-onset ulcerative colitis.

Authors:  Deepal H Dalal; Dana Patton; Janet M Wojcicki; Ann L Clark; Elizabeth A Garnett; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-10       Impact factor: 2.839

3.  Postoperative complications and health care use in children undergoing surgery for ulcerative colitis.

Authors:  Lorraine I Kelley-Quon; Chi-Hong Tseng; Howard C Jen; David A Ziring; Stephen B Shew
Journal:  J Pediatr Surg       Date:  2012-11       Impact factor: 2.545

4.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

5.  Functional outcome and quality of life after ileal pouch-anal anastomosis in children and adults.

Authors:  Simon S B Chew; Richard I Kerdic; Jia-Lin Yang; Edward C P Shi; Graham L Newstead; Philip R Douglas
Journal:  ANZ J Surg       Date:  2003-12       Impact factor: 1.872
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.